Clinical Trial Update: Baricitinib in Hospitalized Covid-19 Patients With Diabetes Mellitus [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating baricitinib in hospitalized COVID-19 pneumonia patients with diabetes mellitus has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Pneumonia

Drugs mentioned

• Baricitinib (baricitinib)

Snippet

Sponsor: Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders | Conditions: COVID-19 Pneumonia | Phase 3 | Status: WITHDRAWN